Late Effect
12
3
3
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (12)
Neurocognitive Deficit After Paediatric Transplantation: Understanding the Role of Environment and Physical Function
eHealth Insomnia Intervention for Adult Survivors of Childhood Cancer
The Swiss Childhood Cancer Survivor Study - Follow-up (SCCSS-FollowUp)
Monitoring Neurocognitive Dysfunction and the Impact of Metabolism and Physical Capacity After Paediatric HSCT
Cardiotoxicity and Other Late Effects After Radiotherapy and Immuno-chemoTherapy in Non-Hodgkin lYmphoma
Testicular Function and Semen Quality in Male Childhood and Adolescent Cancer Survivors
PCSP Implementation Study
An Individualised Treatment vs. a Minimal Program in Women With Late-term Shoulder Impairments After Breast Cancer.
Health-related Quality of Life and Late Effects Among SURVivors of Cancer in Adolescence and Young Adulthood: The SURVAYA Study
Strength Training as Prevention and Treatment of Late Effects in Long-term Survivors of Pediatric HSCT.
Genetic Risks for Childhood Cancer Complications in Switzerland
Impact on Quality of Life of Long-term Ototoxicity in Cancer Survivors